Vertex has expanded the pool of countries where it has negotiated a “portfolio-based” pricing and reimbursement deal for its products. The company has reached an agreement in Denmark, where the public procurement body, Amgros, is keen to explore new ways of tackling high drug prices.
The deal will give access to all Vertex’ current CFTR modulator medicines, including Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) as well...








